08475794 is referenced by 23 patents and cites 141 patents.

Disclosed herein are compositions and methods of use comprising combinations of anti-CD74 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD74 antibody or may be separately administered, either before, simultaneously with or after the anti-CD74 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80, IL-6, CXCR4 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD74 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD74 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD74 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD74 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease, type 1 or type 2 diabetes.

Title
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
Application Number
13/209954
Publication Number
8475794 (B2)
Application Date
August 15, 2011
Publication Date
July 2, 2013
Inventor
Edmund A Rossi
Woodland Park
NJ, US
David M Goldenberg
Mendham
NJ, US
Chien Hsing Chang
Downingtown
PA, US
Agent
Richard A Nakashima
Assignee
IBC Pharmaceuticals
NJ, US
IPC
C07K 16/46
C07K 19/00
C07K 16/28
A61P 35/02
A61K 39/00
A61K 39/395
View Original Source